Search

A patent application has been submitted for new therapeutic methods to treat acute myeloid leukemia (AML). The method involves using genetically modified T cells to target and kill cancer cells more effectively. By targeting specific molecules expressed in AML cells, the therapy can selectively target cancer cells while preserving healthy cells. The research aims to improve the prognosis for AML patients and address relapse and drug resistance. The patent application describes methods involving editing the genome of stem cells and administering antibodies or immune cells to improve the effectiveness of AML treatment. [Extracted from the article]